Health

STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 11:22:23 UTC.

Briefings

Ionis Pharmaceuticals suffered a $1 billion market value loss after significantly underestimating sales for its potential blockbuster drug Tryngolza. The company projected only $50 million in annual sales by year-end, whereas Wall Street analysts expected $21 million in the third quarter. Shares dropped approximately 25% from a high of over $39. The stock reaction was immediate and severe, reflecting a sharp correction in market sentiment following the announcement.

Key points

• Ionis Pharmaceuticals lost over $1 billion in market value following a sales projection cut for Tryngolza.
• Third quarter sales of $9 million fell significantly below Wall Street consensus of $21 million.

Context

Ionis Pharmaceuticals is a biotech firm developing Tryngolza, a drug targeting triglycerides. The company previously forecast $100-$110 million in annual sales, which were substantially exceeded by actual third-quarter results of $9 million, leading to a sharp stock decline.

Limitations

Market data reflects Monday's trading activity; specific analyst quotes are not provided. The stock price drop of 25% is an observed reaction, not a forecast. The $1 billion loss represents a market value fluctuation rather than a confirmed financial loss. No additional background on the drug's development stage or regulatory status is supplied.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/11/2026, 10:51:00 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifls5ev7rwfrjgv4mbscppku5s6x765ibrco6j3zz53x62z3npzqm